148 related articles for article (PubMed ID: 3330094)
1. Immunoregulating peptides II. In vitro effects of TP5 analogs on E-rosette formation and cell division.
Denes L; Szende B; Ember J; Major J; Szporny L; Hajos G; Nyeki O; Schon I; Lapis K; Kisfaludy L
Immunopharmacol Immunotoxicol; 1987; 9(1):1-18. PubMed ID: 3330094
[TBL] [Abstract][Full Text] [Related]
2. The effect of TP-3 (Arg-Lys-Asp), TP-4 (Arg-Lys-Asp-Val), and TP-5 on the metastatic capacity of intravenously injected Lewis lung tumor cells.
Szende B; Lapis K; Pal K; Sipos L; Denes L; Kisfaludy L
Immunopharmacol Immunotoxicol; 1987; 9(1):19-24. PubMed ID: 3330095
[TBL] [Abstract][Full Text] [Related]
3. The effect of TP-5 and its analogs on skin grafts in mice.
Szende B; Kisfaludy L; Lapis K; Dénes L; Szporny L; Nyéke O; Schön I; Hajós G; Ember J; Constantin M
J Immunopharmacol; 1985; 7(1):67-78. PubMed ID: 3891868
[TBL] [Abstract][Full Text] [Related]
4. Effect of thymopoietin pentapeptide on low reversible E-rosette forming cells of rheumatoid arthritis patients. -I) In vitro study.
Auteri A; Laghi Pasini F; Pasqui AL; Bilenchi R; Di Perri T
Boll Soc Ital Biol Sper; 1980 Feb; 56(4):308-11. PubMed ID: 7018514
[No Abstract] [Full Text] [Related]
5. Immunomodulatory activity of a potent thymopentin analog: disulphide bridged beta-mercaptopropionyl-arginyl-lysyl-aspartyl-valyl-tyrosyl-cysteine amide.
Wieczorek Z; Zimecki M; Trojnar J; Siemion IZ
Pol J Pharmacol; 1996; 48(1):31-8. PubMed ID: 9112625
[TBL] [Abstract][Full Text] [Related]
6. Effects of thymopoietin pentapeptide on low reversible E-rosette forming cells of rheumatoid arthritis patients.-II) In vivo study.
Auteri A; Laghi Pasini F; Pasqui AL; Bilenchi R; Di Perri T
Boll Soc Ital Biol Sper; 1980 Feb; 56(4):312-5. PubMed ID: 7018515
[No Abstract] [Full Text] [Related]
7. Comparison of the in vitro effects of thymopoietin pentapeptide and levamisole on peripheral E-rosette forming cells.
Verhaegen H; De Cock W; De Cree J; Goldstein G
Thymus; 1980 Jan; 1(4-5):195-204. PubMed ID: 7445020
[TBL] [Abstract][Full Text] [Related]
8. Biologically active analogs of thymopentin with enhanced enzymatic stability.
Heavner GA; Kroon DJ; Audhya T; Goldstein G
Peptides; 1986; 7(6):1015-9. PubMed ID: 3031628
[TBL] [Abstract][Full Text] [Related]
9. Syntheses and effects of a thymopoietin II fragment and its analogs on the impaired T-cell transformation in a patient with common variable immunodeficiency.
Abiko T; Shishido H; Sekino H
J Appl Biochem; 1985 Dec; 7(6):408-22. PubMed ID: 3879489
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological induced depression of E-rosette forming cells (RFC) of normal healthy subjects. Restoration by levamisole and thymopoietin pentapeptide.
Laghi Pasini F; Auteri A; Ceccatelli L; Di Perri T
Boll Soc Ital Biol Sper; 1980 Feb; 56(4):316-22. PubMed ID: 7018516
[TBL] [Abstract][Full Text] [Related]
11. Structural requirements for the biological activity of thymopentin analogs.
Heavner GA; Audhya T; Kroon D; Goldstein G
Arch Biochem Biophys; 1985 Oct; 242(1):248-55. PubMed ID: 2996431
[TBL] [Abstract][Full Text] [Related]
12. [Conformation states of thymopentin and its synthetic analogs].
Akhmedov NA; Khalilova NM; Popov EM
Mol Biol (Mosk); 1987; 21(1):159-63. PubMed ID: 3553894
[TBL] [Abstract][Full Text] [Related]
13. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets.
Cooper KD; Kang K; Hanifin JM
Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971
[TBL] [Abstract][Full Text] [Related]
14. Interaction of thymopoietin peptides with the specific receptor of facteur thymique serique (FTS).
Gastinel LN; Pleau JM; Goldstein G; Bach JF
Thymus; 1983 Mar; 5(2):78-87. PubMed ID: 6304947
[TBL] [Abstract][Full Text] [Related]
15. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G
J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507
[TBL] [Abstract][Full Text] [Related]
16. Thymopentin and splenopentin as immunomodulators. Current status.
Singh VK; Biswas S; Mathur KB; Haq W; Garg SK; Agarwal SS
Immunol Res; 1998; 17(3):345-68. PubMed ID: 9638477
[TBL] [Abstract][Full Text] [Related]
17. Restoration of the impaired lymphocyte stimulation in old people by thymopoietin pentapeptide.
Verhaegen H; De Cock W; De Cree J; Goldstein G
J Clin Lab Immunol; 1981 Sep; 6(2):103-5. PubMed ID: 7026790
[TBL] [Abstract][Full Text] [Related]
18. Stimulation by thymopoietin oligopeptides of lectin-dependent cell-mediated cytotoxicity in patients with systemic lupus erythematosus.
Perl A; Gonzalez-Cabello R; Nékám K; Gergely P; Fehér J
J Clin Lab Immunol; 1985 Nov; 18(3):119-22. PubMed ID: 3910838
[TBL] [Abstract][Full Text] [Related]
19. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
[TBL] [Abstract][Full Text] [Related]
20. Proton NMR investigation of Ln3+ complexes of thymopoietin 32-36.
Vaughn JB; Stephens RL; Lenkinski RE; Krishna NR; Heavner GA; Goldstein G
Biochim Biophys Acta; 1981 Nov; 671(1):50-60. PubMed ID: 7030403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
